The CHIRAL project addresses the critical challenge of producing enantiomerically pure molecules, which are essential building blocks for bioactive compounds such as pharmaceuticals. Despite advancements in the field, synthesizing the desired enantiomer often requires complex and costly processes. The CHIRAL project aims to revolutionize this area by introducing a novel approach that leverages the ability of crystals to self-sort molecules, using crystal growth to preferentially crystallize the desired enantiomer while suppressing the undesired one.
To achieve this, CHIRAL integrates crystallization processes with racemization reactions, where undesired enantiomers can be converted into desired ones during crystallization. Key objectives include identifying crystallization conditions that favor the desired enantiomer and optimizing racemization reactions to complement the crystallization process.
When successful, CHIRAL will provide groundbreaking insights into fundamental crystallization processes, offering practical and scalable methods for producing enantiomerically pure building blocks. These advancements are expected to significantly reduce costs and complexity in the production of pharmaceuticals and other bioactive compounds, enhancing their accessibility and impact on daily life.